| 主权项 |
1. A method of selecting the group of cancer patients based on the level of CRBN expression within the cancer, wherein said method comprises:
obtaining a biological sample of the cancer from the patient; determining whether CRBN is present in the sample, wherein said determining is performed by contacting the cancer with an isolated antibody that immunospecifically binds to an epitope in CRBN, wherein the epitope has the amino acid sequence SEQ ID NO:1, and wherein the antibody comprises: (i) a heavy chain having the amino acid sequence depicted in SEQ ID NO:5 or 9, or (ii) a light chain having the amino acid sequence depicted in SEQ ID NO:7 or 11; diagnosing the patient as having a drug-sensitive cancer if a higher than baseline level of the CRBN is determined to be present in the sample; and administering a therapeutically effective amount of the drug to a patient diagnosed as having a drug-sensitive cancer; wherein the cancer patients are multiple myeloma, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, melanoma or solid tumor patients; and wherein the drug is thalidomide, lenalidomide, pomalidomide or 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, a stereoisomer thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. |
